Protagonist Therapeutics, Inc.PTGXNASDAQ
Loading
PTGX Revenue Growth (YoY Quarterly)•-95.64%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-95.64%
-96.4pp
-95.86%
-96.7pp
-134.04%
-134.0pp
-139.72%
-139.7pp
-133.71%
-133.7pp
-132.70%
-132.7pp
-134.85%
-134.8pp
+2.00%
-1.2pp
-4.27%
-7.5pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +184.40% | -88.89% | +33.09% | +0.79% | -95.64% |
| Gross Profit Growth | +184.40% | -88.89% | +33.09% | +0.79% | -95.86% |
| EBITDA Growth | +433.13% | -109.23% | +0.00% | +0.00% | -134.04% |
| Operating Income Growth | +450.05% | -109.36% | +0.00% | +0.00% | -139.72% |
| Net Income Growth | +381.70% | -105.62% | +0.00% | +0.00% | -133.71% |
| EPS Growth | +368.89% | -105.57% | +0.00% | +0.00% | -132.70% |
| EPS Diluted Growth | +350.00% | -105.83% | +0.00% | +0.00% | -134.85% |
| Weighted Average Shares Growth | +3.21% | +3.46% | +3.60% | +3.25% | +2.00% |
| Weighted Average Shares Diluted Growth | +7.46% | -0.99% | +3.60% | +3.25% | -4.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -272.04% | +0.00% | -110.71% | +0.00% | +0.00% |
| Free Cash Flow Growth | -274.06% | +0.00% | -111.02% | +0.00% | +0.00% |
| Receivables Growth | +1530.76% | -90.98% | +1941.68% | -78.16% | -97.33% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +108.05% | +17.93% | +16.82% | +16.20% | -10.05% |
| Book Value per Share Growth | +94.33% | +18.83% | +19.12% | +17.53% | -10.75% |
| Debt Growth | +852.32% | +2358.87% | +2.81% | -1.39% | -5.00% |
| R&D Expense Growth | +20.78% | +6.40% | +10.49% | +11.21% | +32.82% |
| SG&A Expenses Growth | +11.20% | -21.27% | +11.77% | +9.57% | +23.50% |
1 / 4